Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Losartan 150 mg/day reduced left ventricular ejection fraction, intolerance to ACE inhibitors, and the rate of death and/or hospital admission for heart failure in patients with CHF more than did losartan 50 mg/day, thereby demonstrating the potential value of uptitrating ARB doses to confer clinical benefit.

Effects of High- vs Low- dose ARBs on Outcomes in Patients with CHF